China’s booming pet economy is entering an unexpected new phase as rising concern over overweight cats pushes pharmaceutical firms to explore weight loss treatments designed specifically for felines. What began as a social media obsession with adorably pudgy pets is now prompting serious
Mandi’s IPO plan arrives at a time when Hong Kong’s capital markets are experiencing a remarkable revival. According to data from the London Stock Exchange Group, equity capital activity in the city has reached around seventy three billion dollars so far this year,
China’s rapid rise in clinical research is reshaping the global pharmaceutical landscape. With its current clinical trial capacity now comparable to that of the United States, the country is increasingly viewed as a prime destination for cutting edge drug development, international collaboration and
China’s startup ecosystem has entered a new era defined by deep technology, sustainability, and global ambition. After a decade of consumer app dominance, a new generation of companies is emerging across artificial intelligence, biotechnology, and green energy. These firms are not just chasing
Gene therapy, precision medicine, and biotech startups are Beijing’s next frontier industries. The Next Growth Engine China’s economic playbook is shifting. After decades of growth fueled by manufacturing and property, Beijing is betting on biotechnology as the next frontier industry. From gene therapies
